Successful interferon-gamma therapy in a chronic granulomatous disease (CGD) patient suffering from Staphylococcus aureus hepatic abscess and invasive Candida albicans infection

Scandinavian Journal of Infectious Diseases
B E Malmvall, P Follin

Abstract

A 16-year old boy with an early history of recurrent lower respiratory tract infections exhibited symptoms of prolonged septic fever and liver abscess. Cultures from liver puncture were positive for Staphylococcus aureus, and the patient initially responded to antibacterial therapy. After a period of 4 months, however, the infection relapsed, and further treatment with broad antibacterial, antifungal and tuberculostatic drugs was ineffective. Neither soluble nor particulate stimuli were found to elicit the respiratory burst response in granulocytes from the patient. Spectral analysis of granulocyte cytochrome-b confirmed the diagnosis of chronic granulomatous disease. Since the patient's physical condition deteriorated severely during the prolonged (10-week) septic course, immunosupportive interferon-gamma was added to the anti-microbial therapy. With this regime, the fever subsided and the general condition of the patient improved dramatically. He could be discharged from hospital 9 weeks after the introduction of interferon-gamma and was, at an elective follow-up control 1 month later, convalescing and showed no signs of active infection.

References

Sep 21, 1991·JAMA : the Journal of the American Medical Association·S BaronT K Hughes
Feb 21, 1991·The New England Journal of Medicine·UNKNOWN International Chronic Granulomatous Disease Cooperative Study Group
Mar 16, 1990·JAMA : the Journal of the American Medical Association·J I Gallin, H L Malech
Mar 30, 1990·Biochemical and Biophysical Research Communications·P Follin, C Dahlgren
Jun 1, 1990·The Journal of Infectious Diseases·R A Clark
Jul 1, 1988·Proceedings of the National Academy of Sciences of the United States of America·J M SechlerJ I Gallin
Sep 1, 1986·Journal of Advanced Nursing·A J Berry, C L Metcalf

❮ Previous
Next ❯

Citations

Mar 29, 2014·BMC Infectious Diseases·Corine E DelsingMihai G Netea
Aug 20, 2010·Medical Mycology·Guillaume MonneretMihai G Netea
Jun 2, 2018·Biomolecular Concepts·Gunjan KakBrijendra K Tiwari
Jun 7, 2007·European Journal of Pediatrics·Charalampos AntachopoulosEmmanuel Roilides
Jun 27, 2002·Expert Opinion on Pharmacotherapy·David Goldblatt
Sep 30, 2000·Clinical and Experimental Immunology·D Goldblatt, A J Thrasher
Oct 20, 2020·Frontiers in Immunology·Derry K Mercer, Deborah A O'Neil
Jul 2, 2021·Emerging Topics in Life Sciences·Derry K MercerDouglas Fraser-Pitt

❮ Previous
Next ❯

Related Concepts

Related Feeds

Candidiasis

Candidiasis is a common fungal infection caused by Candida and it can affect many parts for the body including mucosal membranes as well as the gastrointestinal, urinary, and respiratory tracts. Here is the latest research.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Candidiasis (ASM)

Candidiasis is a common fungal infection caused by Candida and it can affect many parts for the body including mucosal membranes as well as the gastrointestinal, urinary, and respiratory tracts. Here is the latest research.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

CRISPR & Staphylococcus

CRISPR-Cas system enables the editing of genes to create or correct mutations. Staphylococci are associated with life-threatening infections in hospitals, as well as the community. Here is the latest research on how CRISPR-Cas system can be used for treatment of Staphylococcal infections.

Candida albicans

Candida albicans is an opportunistic, fungal pathogen of humans that frequently causes superficial infections of oral and vaginal mucosal surfaces of debilitated and susceptible individuals. Discover the latest research on Candida albicans here.